Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic BM-MSC for no-option severe limb ischemia
NL-OMON45407Phase 2Withdrawn
- Sponsor
- University Medical Center Utrecht
- Start
- Jan 2017
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of allogeneic bone marrow-derived mesenchymal stromal cells in chronic limb-threatening ischemia (CLTI) and peripheral artery occlusion (PAD) (2 arms), sponsored by University Medical Center Utrecht. Primary endpoint: Therapy success at 6 months. Planned start Jan 2017; status: withdrawn.
02
Drugs
allogeneic bone marrow-derived mesenchymal stromal cells
03
Conditions
chronic limb-threatening ischemia (CLTI)peripheral artery occlusion (PAD)
Beyond the preview
Go deeper on NL-OMON45407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45407.